Novartis’ Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer

(Reuters) -Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%.

Pluvicto is part of a class of drugs that combines cell-killing radioactive particles with molecules that attach themselves to tumours, a field in which Novartis has a leading position.

(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Sharon Singleton)